Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRĪ± Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity.

Cheng X, Li J, Tanaka K, Majumder U, Milinichik AZ, Verdi AC, Maddage CJ, Rybinski KA, Fernando S, Fernando D, Kuc M, Furuuchi K, Fang F, Uenaka T, Grasso L, Albone EF.

Mol Cancer Ther. 2018 Dec;17(12):2665-2675. doi: 10.1158/1535-7163.MCT-17-1215. Epub 2018 Sep 27.

PMID:
30262588
2.

Engineering humanized antibody framework sequences for optimal site-specific conjugation of cytotoxins.

Spidel JL, Albone EF, Cheng X, Vaessen B, Jacob S, Milinichik AZ, Verdi A, Kline JB, Grasso L.

MAbs. 2017 Aug/Sep;9(6):907-915. doi: 10.1080/19420862.2017.1330734. Epub 2017 May 25.

3.

Generation of therapeutic immunoconjugates via Residue-Specific Conjugation Technology (RESPECT) utilizing a native cysteine in the light chain framework of Oryctolagus cuniculus.

Albone EF, Spidel JL, Cheng X, Park YC, Jacob S, Milinichik AZ, Vaessen B, Butler J, Kline JB, Grasso L.

Cancer Biol Ther. 2017 May 4;18(5):347-357. doi: 10.1080/15384047.2017.1312232. Epub 2017 Apr 10.

4.

Derivatization of agelastatin A leading to bioactive analogs and a trifunctional probe.

Jouanneau M, McClary B, Reyes JC, Chen R, Chen Y, Plunkett W, Cheng X, Milinichik AZ, Albone EF, Liu JO, Romo D.

Bioorg Med Chem Lett. 2016 Apr 15;26(8):2092-7. doi: 10.1016/j.bmcl.2016.02.051. Epub 2016 Feb 23.

Supplemental Content

Loading ...
Support Center